Title: Multicentre phase II studies evaluating imatinib plus hydroxyurea in patients with progressive glioblastoma
Authors: Reardon, D A ×
Dresemann, G
Taillibert, S
Campone, M
van den Bent, M
Clement, Paul
Blomquist, E
Gordower, L
Schultz, H
Raizer, J
Hau, P
Easaw, J
Gil, M
Tonn, J
Gijtenbeek, A
Schlegel, U
Bergstrom, P
Green, S
Weir, A
Nikolova, Z #
Issue Date: Dec-2009
Publisher: Harcourt Publishers
Series Title: British Journal of Cancer vol:101 issue:12 pages:1995-2004
Abstract: BACKGROUND: We evaluated the efficacy of imatinib mesylate in addition to hydroxyurea in patients with recurrent glioblastoma (GBM) who were either on or not on enzyme-inducing anti-epileptic drugs (EIAEDs). METHODS: A total of 231 patients with GBM at first recurrence from 21 institutions in 10 countries were enrolled. All patients received 500 mg of hydroxyurea twice a day. Imatinib was administered at 600 mg per day for patients not on EIAEDs and at 500 mg twice a day if on EIAEDs. The primary end point was radiographic response rate and secondary end points were safety, progression-free survival at 6 months (PFS-6), and overall survival (OS). RESULTS: The radiographic response rate after centralised review was 3.4%. Progression-free survival at 6 months and median OS were 10.6% and 26.0 weeks, respectively. Outcome did not appear to differ based on EIAED status. The most common grade 3 or greater adverse events were fatigue (7%), neutropaenia (7%), and thrombocytopaenia (7%). CONCLUSIONS: Imatinib in addition to hydroxyurea was well tolerated among patients with recurrent GBM but did not show clinically meaningful anti-tumour activity.
ISSN: 0007-0920
Publication status: published
KU Leuven publication type: IT
Appears in Collections:Laboratory of Experimental Oncology
× corresponding author
# (joint) last author

Files in This Item:

There are no files associated with this item.

Request a copy


All items in Lirias are protected by copyright, with all rights reserved.

© Web of science